Effects of daily SKF 38393, quinpirole, and SCH 23390 treatments on locomotor activity and subsequent sensitivity to apomorphine by Mattingly, Bruce A. et al.
0 





Effects of daily SKF 38393, quinpirole, 
and SCH 23390 treatments on locomotor activity 
and subsequent sensitivity to apomorphine* 
Bruce A. Mattingly, James K. Rowlett, and Greg Lovell 
Department of Psychology, 601 Ginger Hall, Morehead State University, Morehead, KY 40351, USA 
Received June 8, 1992 / Final version July 28, 1992 
Abstract. In three experiments, male Wistar rats 
(250--350 g) were injected (SC) daily with the D 1-type 
dopamine receptor agonist, SKF 38393 (0.0, 4.0, 8.0, or 
16.0 mg/kg), the Dz-type dopamine receptor agonist, 
quinpirole (0.0, 0.3, or 3.0 mg/kg), and/or the D 1-type 
dopamine receptor antagonist, SCH 23390 (0.0 or 0.5 
mg/kg) for 8--10 days. After each daily injection, the rats 
were tested for locomotor activity in photocell arenas for 
20 min. Following this subchronic pretreatment, all rats 
were challenged with the mixed dopamine receptor ago-
nist apomorphine (1.0 mg/kg, SC) and tested for loco-
motor activity. SKF 38393 treatments produced a dose-
dependent decrease in locomotor activity which did not 
significantly change across days. Quinpirole also de-
pressed locomotor activity when first°injected, but this 
quinpirole-induced inhibition of activity progressively 
decreased across days. When subsequently. challenged 
with apomorphine, rats in both the SKF 38393 and the 
quinpirole pretreatment groups displayed greater loco-
, motor activity than rats pretreated with only vehicle. 
Although SCH 23390 pretreatments did not affect subse-
quent sensitivity to apomorphine, SCH 23390 completely 
blocked the effect of quinpirole. These results suggest 
that although repeated D 1 receptor stimulation may be 
sufficient to induce behavioral sensitization to apomor-
phine, Dz receptor stimulation also contributes to the 
effect. 
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The repeated administration of drugs that stimulate 
dopamine receptors often results in the development of 
behavioral sensitization (see Robinson and Becker 1986; 
Kaliyas and Weber 1988). This behavioral sensitization 
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effect has been demonstrated in rats !with both direct 
(e.g., apomorphine) and indirect (amphetamine, cocaine) 
dopamine agonists and is characterize<) by a progressive 
augmentation of various drug-induced motor behaviors 
(e.g., Kalivas and Weber 1986; Robipson and Becker 
1986; Mattingly et al. 1988). Although recent evidence 
clearly indicates that stimulation of dopamine receptors 
is neccessary for the development of behavioral sensitiza-
tion (e.g., Kuczenski and Leith 1981; Mattingly and 
Rowlett 1989; Peris and Zahniser 1989), the specific 
drug-induced neurobiological changes mediating the de-
velopment of behavioral sensitization are unknown. 
Dopamine agonists which induce 'the development 
of behavioral sensitization (e.g., apomorphine, am-
phetamine, and cocaine) result in an ihcreased stimula-
tion of both D.-type and Dz-type dopamine receptors. 
In a recent study of apomorphine-induced sensitization, 
we found that concurrent treatments' of rats with the 
D1-type dopamine antagonist, SCH 23390, blocked both 
the acute locomotor-activating effects of apomorphine 
and the development of behavioral sensitization. In con-
trast, the Dz-type dopamine receptor antagonist, sulp-
iride, blocked the acute effects of apomorphine, but did 
not prevent the development of behavioral sensitization 
(Mattingly et al. 1991). Similarly, amphetamine-induced 
behavioral sensitization may be blocked by D,, but not 
D2-type, dopamine receptor antagonists (Stewart and 
Vezina 1989; Vezina and Stewart 1989). These findings, 
of course, suggest that repeated stimulation of the dopa-
mine D 1-type receptor is both necessary and sufficient to 
induce the development of behavioral sensitization. In 
the present study, we tested this assumption by treating 
rats daily with either the selective Ii,-type dopailline 
agonist, SKF 38393 (expt I) or the Dz-type agonist, 
quinpirole (expt 2), and testing for locomotor activity. 
Following this subchronic pretreatm~nt, all rats were 
then tested for locomotor activity afte~ a challenge injec-
tion of the mixed Di/Dz agonist, apomorphine. Based 
upon our. prior work, we expected the rats pretreated 
with SKF 38393, but not quinpirol~, to demonstrate 
behavioral sensitization to apomorphihe. 
I 
Experiments 1 and 2 
Materials and methods 
Subjects. Seventy-three male Wistar albino rats (Harlan Industries, 
Indianapolis, IN) weighitlg between 250 and 350 g served as sub-
jects. All rats were housed individually in hanging wire-mesh cages 
in a colony room with a 12-h light-dark cycle and fqod and water 
available continuously. All behavioral testing.was conducted during 
the light phase of the cycle. 
Apparatus. Activity measures were taken in two BRS/Lehigh Valley 
cylindrical activity drums (Model 145-03). The floor of each drum 
was made of 4 cm diamond-shaped wire mesh and was 60 cm in 
diameter. The interior wall of each drum was painted flat black and 
was 43 cm high. Each drum was located in a separate sound-
attenuated experimental cubicle that was kept dark during testing. 
Two banks of three infrared photocells were mounted on the 
outside of each drum. The six photocell beams were approximately 
12 cm apart arranged in a criss-cross pattern 2.5 cm above the drum 
floor. The photocell banks were connected to back-path eliminator 
diodes. Movement of the rat through a photocell beam sent a single 
pulse to the counters. Simultaneous pulses (i.e., pulses spaced less 
than 0.05 s apart) such as might occur when two beams are broken 
at their intersection were recorded as a single count by this method. 
Thus, locomotor activity was operationalized as the cumulative 
number of photocell interruptions per unit time. 
Drugs. Apomorphine hydrochloride (Sigma) and SKF 38393 (Re-
search Biochemicals) were diss_olved daily in 0.001 N HCL. Apo-
morphine was injected in a volume of 1.0 ml/kg and SKF 38393 was 
injected in a volume of 1.5 ml/kg. Quinpirole hydrochloride (Re-
search Biochemicals) was mixed in distilled H 20· and injected in a 
volume of 1.0 ml/kg. All injections were SC. Control injections were 
given using the appropriate vehicle using the same route and volume 
as the correspon-ding drug injection. 
Design and procedure. At the beginning of experiment I, 48 rats were 
randomly assigned, in equal numbers, to one of four treatment 
groups: 0 (vehicle), 4.0, 8.0, or 16.0 mg/kg SKF 38393. On each of 
the first 10 days of the experiment (pretreatment phase), the rats 
were injected with the appropriate dose of SKF 38393 and then 
tested for locomotor activity 15 min after the injection. Locomotor 
activity measurements were taken for 20 min each day. On day 11 
of the experiment all rats. were given a challenge injection of apo-
morphine (1.0 mg/kg) and then tested for activity 15 min later. 
Experiment 2 was the same as experiment 1 except three groups of 
rats (N~8-9/group) were given either 0 (vehicle), 0.3, or 3.0 mg/kg 
quinpirole during the pretreatment phase. 
Data analysis. Significant differences among the groups in mean 
activity counts across days were determined with mixed-factor 
analyses of variance (ANOV A) using drug treatment group as a 
between factor and daily test session as a repeated measure. When 
appropriate, additional one-way ANOVAs or Neuman-Keuls post 
hoc test were performed. 
Results 
Expt I: chronic SKF 38393 and activity. The mean activ-
ity counts for the four groups injected daily with various 
doses of SKF 38393 across the first ten test days are 
shown in Fig. I. As may be seen in this figure, rats 
injected with SKF 38393 were significantly less active 
than the vehicle control rats on the first test day. More-
over, this drug-induced decrease in locomotor activity 
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Fig. 1. Mean activity counts per 20 min' session across the 
10 pretreatment days for rats (N= 12/group)' injected with either 
vehicle (0-0) or SKF 38393. SKF 38393: 4.0 mg/kg (•-•); 
8.0 mg/kg ( .l-.l); 16.0 mg/kg (•-•). The standard error of the 
mean for the groups' activity on day 10 was 65.25 
changed across the ten daily injection-test sessions. That 
is, although the groups gradually decre'.ased activity with 
repeated testing, the activity of the SKF 38393 groups, 
particularly the 8.0 and 16.0 mg/kg groups, remained 
significantly lower than that of the vehicle control rats. 
The ANOVA performed on these data revealed a signifi-
cant drug effect [F(3, 44)= 12.10, P<o:oool], day effect, 
[F(9, 396)= 50.64, P< 0.0001], and Drug x Day interac-
tion, [F(27,396)= 1.89, P<0.01]. This latter interaction 
was largely due to the fact that the groups decreased 
activity at slightly different rates over the first 3 test days. 
Expt I: apomorphine challenge of SKF 38393 pretreated 
rats. The mean activity counts of the four pretreatment 
groups after a challenge injection of apomorphine 
(1.0 mg/kg) on test day 11 are shown in Fig. 2. As shown 
in this figure, rats previously given ten daily injections of 
SKF 38393 displayed significantly greater levels of loco-
motor activity in response to the apomorphine challenge 
injection than rats previously treated ~ith only vehicle. 
As expected, the ANOV A performed :on these data re-
vealed a significant drug effect, [F(3, 44) = 3.55, P< 0.05]. 
Subsequent analysis of this drug effect with Newman-
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Fig. 2. Mean activity counts ( + SEM) during the 20 min session 
following a challenge injection of apoinorphine for rats 
(N= 12/group) previously treated daily with e'ither vehicle or SKF 
38393. (*P<0.05 vs 0 mg/kg group) ' 
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pretreatment groups were significantly more active fol-
lowing apomorphine than the vehicle control group 
(Ps<0.05). 
Expt 2: chronic quinpirole and activity. The mean activity 
counts for the three groups of rats injected daily with 
either quinpirole or vehicle are displayed in Fig. 3. As 
may be seen in this figure, quinpirole induced a signifi-
cant depression in locomotor activity following the first 
injection. This quinpirole-induced inhibition of loco-
motor activity, however, progressively decreased with 
repeated injections. Indeed, by day 4 of testing the rats 
injected with quinpirole did not differ significantly from 
those injected with vehicle, and by the end of testing 
quinpirole-treated rats were more active than vehicle-
treated rats. The ANOV A performed on these data 
indicated that the main effect of drug was not significant. 
As expected, however, both the main effect of 
day and the Drug x Day interaction were significant 
[F(9,198)= 13.95, P<0.0001, and F(18, 198)=9.49, 
P< 0.0001, respectively]. To further analyse this interac-
tion, a one-way ANOV A was performed on the rats' 
activity scores on the last pretreatment test day (10). The 
results of this analysis revealed no significant differences 
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Fig. 3. Mean activity counts per 20 min session across the 
10 pretreatment days for rats (N=8-9/group) injected with either 
vehicle (o-o) or quinpirole. Quinpirole: 0.3 mg/kg (•-•); 
3.0 mg/kg (.&.-.&). The standard error of the mean for the groups' 
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Fig. 4. Mean activity counts per 20 min session ( + SEM) following 
a challenge injection of apomorphine for the three groups of rats 
(N = 8-9 each) previously treated daily with either vehicle or quin-
pirole. (*P<0.05 vs 0 mg/kg group) 
pirole-treated rats were not significantly more,active than 
the vehicle-treated rats on this test day."· 
Expt 2: apomo1phine challenge of quinpirole pretreated 
rats. The mean activity counts of the three quinpirole 
pretreatment groups after a challenge injection of apo-
morphine on day 11 of testing are shown in Fig. 4. It is 
evident from this figure that the rats pretreated for 
10 days with 3.0 mg/kg quinpirole displayed significantly 
greater locomotor activity in response to a challenge 
injection of apomorphine than did either the vehicle-
control group or the 0.3 mg/kg quinpirole pretreatment 
group. As expected, the ANOVA performed on these 
data revealed a significant drug effect [F(2,24)= 3.75, 
P< 0.05]. 
Experiment 3 
In experiment 2, rats pretreated with the D 2 receptor 
agonist, quinpirole displayed significantly greater levels 
of locomotor activity following an apomorphine injec-
tion than did rats pretreated with vehicle. This finding 
was unexpected because our previous work had indicated 
that rats repeatedly treated with the mixed D 1/D2 dopa-
mine receptor agonist, apomorphine, along with the 
selective D1 dopamine antagonist SCH 23390 do not 
become sensitized to apomorphine (Mattingly et al. 
1991). This apparent discrepancy in the effects of re-
peated D2 receptor stimulation may be related to the 
presence or absence of D 1 "tone". That is, repeated D 2 
receptor stimulation may have been effective in expt 2 
because th.e D 1 receptors were not blocked as they were 
in our previous study. If so, then the effects of repeated 
quinpitole treatments, like apomorphine treatments, 
should be blocked by concurrent treatments with the D 1 
receptor antagonist, SCH 23390. In experiment 3, 
therefore, groups of rats were injected daily with quin-
pirole and/or SCH 23390 for 8 days and then tested for 
locomotor activity after a challenge injection of apomor-
phine. 
Materials and methods 
Subjects, apparatus, and drugs. The subjects were 32 male Wistar 
albino rats (Harlan Industries, Indianapolis, IN) weighing between 
250 and 300 g at the beginning of the experiment. The apparatus 
was the same as in the preceding experiments. Likewise, quinpirole 
and apomorphine were obtained, prepared, and administered as 
described previously. SCH 23390 (Research Biochemicals, Inc.) was 
dissolved daily in distilled H 2 0 and injected SC in a volume of 
1.0 ml/kg. 
Design and procedure. The rats were randomly assigned, in equal 
numbers, to one of four groups comprising the two (SCH 23390 
dose: 0 or 0.5 mg/kg)xtwo (quinpirole dose: 0 or 3.0 mg/kg) 
factorial design. On day 1 of the pretreatment phase each rat was 
first injected with either vehicle or SCH 23390 and returned to its 
home cage. Fifteen minutes later each rat was injected with either 
quinpirole or vehicle and again returned to its home cage. Fifteen 
minutes after the second injection each rat was placed into the 
activity drum and activity counts were recorded for 20 min. This 
injection-test procedure was repeated daily for 8 days. On day 9, all 
rats were given a challenge injection of apomorphine (1.0 mg/kg) 
and tested for activity 15 min after the injection. 
Results 
Expt 3: quinpiro/e, SCH 23390, and activity. The mean 
activity counts of the four groups across the eight pre-
treatment sessions are presented in Fig. 5. As may be seen 
in this figure, rats injected with SCH 23390 and/or quin-
pirole were significantly less active on day I than rats 
injected with only vehicle. Further, the S_C~ 233?0-m-
duced inhibition of locomotor activity did not sigmfi-
cantly change across the 8 pretreatment days. In con-
trast, the quinpirole-induced inhibition of locomotor ac-
tivity decreased significantly across the pretreatment 
days for rats injected with vehicle, but not for those 
injected with SCH 23390. That is, concurrent S_CH 233_90 
treatments completely blocked the increase m act!V!ty 
observed across days in quinpirole-injected rats. The 
three-factor ANOVA performed on these data revealed 
a significant main effect for SCH 23390 [F(l, 28) = 74.60, 
p < 0.000 l ], and several significant interactions including 
the SCH 23390 x Quinpirole x Day interaction [F(7, 196) 
= 8.35, P < 0.0001]. To further analyse this latter interac-
tion a separate ANOVA was performed on the last 
pret~eatment day (day 8) al on~. Consistent _with the 
above interpretation, this analysis revealed a sigmficant 
main effect of SCH 23390 [F(l, 28)= 50.37, P<0.0001], 
however neither the main effect of quinpirole nor the 
SCH 23390 x Quinpirole interaction was significant 
[Fs < 1.00]. Thus, at the end of the_ pretr~ahnent phase, 
rats injected with SCH 23390 remamed sigmficantly less 
active then the vehicle control rats, whereas rats treated 
daily with only quinpirole did not significantly differ 
from rats injected daily with only vehicle. 
Expt 3: apomorphine challenge of SCH 23390/quinpirole 
pretreated rats. The mean activity counts of the four 
groups of rats after the challenge injection of apomor-
phine on day 9 of testing are presente<J m Fig. 6. Consis-
tent with the results of experiment 2, rats pretreated for 
8 days with only quinpirole displayed significantly 
Fig. S. Mean activity counts per 20 min session across t?~ 8 pretre~t­
ment days for the four groups of rats (N=8/grqup) 1~1ected d~dy 
with either vehicle (V) or SCH 23390 (S) followed by either vehicle 
or quinpirole (Q) (0-'-0) V-V; (•-•) V-Q; (D-D) S-V; (•-•) 
S-Q. The stardard error of the mean for the groups' activity on day 
8 was IOI 
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Fig. 6. Mean activity counts per 20 min session ( + SEM) following 
a challenge injection of apomorphine for groups of rats 
(N = 8/group) previously treated for 8 d~ys with eithe: v~hicle (V) 
or SCH 23390 (S) followed by either vehicle (V) or qump1role (Q). 
(*P<0.05 vs V-V group) 
greater locomotor activity following ~n injection of apo-
morphine than did rats pretreated with only vehicle. In 
contrast, the activity of rats pretreated with only 
SCH 23390 for 8 days did not differ significantly from the 
vehicle-only group on this test day. Mdre important, rats 
pretreated with both SCH 23390 and quinpirole for 
8 days did not differ from the vehicle control group. In 
other words concurrent .treatments of rats with 
SCH 23390 blocked the effects of repeated quinpirole 
treatments on apomorphine-induced activity. Consistent 
with this interpretation, the ANOVA performed on these 
data revealed a significant main effect of SCH 23390 
[F(l, 28)=8.44, P<0.01] and a ·significant SCH 
23390 x Quinpirole interaction [F(l, 28) = 8.01, P.< 0.01]. 
A Neuman-Keuls analysis of this significant interaction 
indicated that the vehicle-quinpirole rats were signifi-
cantly more active than the other thr~e groups, [Ps < 
0.05]. None of the other group comparisons were signifi-
cant. 
It might be noted that in this experiment the rats 
previously given only vehicle displayed ¥re~ter activity 
following the apomorphine challenge mject10n than m 
either of the preceding two experiments. Moreo_ver, m 
contrast to the first two experiments, apomorphme did 
not produce a decrease in activity in vehicle rats relative 
to their activity level following vehicle, on the precedmg 
day. This variability in the initial effects of apomorphme 
is not unusual. Moreover, the lack of an apomorphme-
induced increase in activity following the first injection 
of apomorphine is consistent with our previous work (see 
Mattingly et al. 1988, 1991; Mattmgly and Gots1ck 1989; 
Rowlett et al. 1991). It should be emphasized, however, 
that the development of behavioral sensitization to apo-
morphine is a highly reliable and robust phenomenon, 
and despite changing baselines, the relative effects of 
various treatments on apomorphine-iqduced locomotor 
activity have also been reliable across experiments (cf, 
quinpirole groups in Figs. 4 and 6). 
' 
Discussion I 
It is evident from the present results that selective stimu-
lation of the D 1-type dopamine receptor with SKF 38393 
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in rats significantly inhibited locomotor activity, More-
over, this inhibition was dose-dependent and did not 
significantly change with repeated treatments. The D 2-
type dopamine receptor agonist, quinpirole, also de-
creased locomotor activity when first administered, but 
this inhibition rapidly decreased with repeated treat-
ments. In fact, with repeated treatments quinpirole ap-
peared to have a stimulating effect on locomotor activity 
relative to the vehicle treated rats. Whether this increase 
in activity with repeated quinpirole treatments should be 
interpreted as tolerance or sensitization, however, is un-
clear, since the quinpirole treated rats were not signifi-
cantly more active than the vehicle treated rats at the end 
of training. Although the time course is quite different, 
the direct D,-type dopamine receptor agonist bromo-
criptine also depresses locomotor activity when first 
presented, bnt with repeated treatments results in an 
increase in locomotor activity (Hoffman and Wise 1992). 
The inhibition oflocomotor activity induced by quin-
pirole was expected and may be related to the stimulation 
of D 2-type autoreceptors. Dopamine autoreceptors ap-
pear to be part of a negative feedback loop which, when 
stimulated, result in a decrease in the synthesis and re-
lease of dopamine as well as a decrease in the firing rate 
of dopamine cells (see Wolf and Roth 1987; Drukarch 
and Stoof 1990; Lynch 1991, for reviews). Dopamine 
autoreceptors are generally considered to be of the D 2 -
type (but see Diana et al. 1991) and appear to be more 
sensitive to various dopamine agonists compared to post-
synaptic D 2-type receptors (see Skirboll et al. 1979; 
Drukarch and Stoof 1990). Thus, although high doses of 
direct agonists such as apomorphine often increase loco-
motor activity, low doses typically result in an inhibition 
of activity due to selective autoreceptor stimulation (e.g., 
Mattingly et al. 1988). The initial inhibition of activity 
induced by quinpirole in the present study is consistent 
with this view. Moreover, the rapid tolerance that de-
veloped to the inhibitory effects of quinpirole also sug-
gests autoreceptor involvement. That is, a number of 
electrophysiological studies have demonstrated that 
autoreceptors rapidly become subsensitive to dopamine 
agonists with repeated exposure (e.g., Rebec and Lee 
1982). Hence, the progressive increase in activity ob-
served in the present study with repeated quinpirole 
treatments may be related to the development of autore-
ceptor subsensitivity. 
As discussed above, low doses of the mixed Di/D 2 
dopamine receptor agonist apomorphine usually 
produce hypoactivity and this decrease in activity has 
generally been attributed to selective D 2 autoreceptor 
stimulation (e.g., Radhakishun and Van Ree 1987). The 
present results, however, indicate that stimulation of 
Di-type dopamine receptors with SKF 38393 can also 
produce locomotor hypoactivity. This finding suggests 
that the inhibitory effects of low doses of some dopamine 
agonists might be due to Di postsynaptic receptor stimu-
lation rather than to simply D2 autoreceptor activation. 
Consistent with this view, other recent work suggests that 
the behavioral effects of low dose apomorphine treat-
ments cannot be explained exclusively by selective auto-
receptor activation (see Stahle and Ungerstedt 1989, 
1990; Lynch 1991). Alternatively, it is possible that SKF 
38393 reduced activity in the present study because the 
doses used stimulated both postsynaptic Di receptors 
and D 2 autoreceptors. If this were the case, however, the 
SKF 38393-induced inhibition of activity should have 
progressively diminished over days in a manner similar 
to quinpirole. As noted previously, the SKF 38393-in-
duced decrease in locomotor activity did not significantly 
change with repeated treatments. Likewise, SKF 38393-
induced grooming behavior in rats does not significantly 
increase with daily treatments (White et al. 1990; Niese-
wander et al. 1991 ). Thus, the possibility exists that the 
hypoactivity observed after mixed agonist treatments is 
mediated in part by Di receptors (cf, Vezina et al. 1991). 
Although SKF 38393 treatments decreased locomotor 
activity across the IO pretreatment days, SKF 38393-pre-
treated rats displayed significantly greater levels of activ-
ity in response to an apomorphine-challenge injection 
than rats pretreated with only vehicle. This finding is 
consistent with our previous work in which rats were 
treated daily with the mixed dopamine agonist apomor-
phine along with the D 2 receptor antagonist sulpiride 
(Mattingly et al. 1991). Although this combination of 
drugs resulted in an acute decrease in locomotor activity 
across days, rats treated in this manner displayed a sen-
sitized locomotor response to a subsequent challenge 
injection of apomorphine. Together these results suggest 
that repeated stimulation of the dopamine Di-type re-
ceptor alone is sufficient to induce the development of 
behavioral sensitization to the mixed dopamine agonist 
apomorphine. Based upon both behavioral aud elec-
trophysiological data, other researchers have also con-
cluded that repeated dopamine Di receptor stimulation 
may be the crucial factor neccessary for the induction of 
agonist-induced behavioral sensitization (e.g., Braun and 
Chase 1988; Criswell et al. 1989; Henry et al. 1989; 
Stewart and Vezina 1989; Vezina and Stewart 1989; 
White et al. 1990; Henry and White 1991). It should be 
noted, however, that SKF 38393 is not a full but rather 
a partial Di dopamine receptor agonist. Consequently, 
it might be argued that the increase in sensitivity to 
apomorphine observed in the present study following 
repeated SKF 38393 treatments could be due to an up-
regulation of Di dopamine receptors. There are at least 
two arguments against this alternative interpretation. 
First, although an increase in dopamine Di receptors in 
the substantia nigra has been ·reported following chronic 
methamphetamine treatments (Ujike et al. 1991 ), chronic 
administration of SKF 38393 alone does not alter either 
the number or affinity of Di receptors (Rowlett, Mat-
tingly, and Bardo, submitted for publication; Neisewan-
der et al. 1991). Second, if the increase in sensitivity to 
apomorphine was due to the partial agonist effects of 
SKF 38393, then repeated SCH 23390 treatments should 
produce a similar increase in sensitivity to apomorphine. 
Repeated treatment with the dopamine Di receptor an-
tagonist SCH 23390, however, does not result in an 
increased activity response to a subsequent challenge 
injection of apomorphine (see expt 3; Mattingly et al. 
1991 ). 
As discussed previously, we have found that the de-
velopment of behavioral sensitization to the mixed D 1/ 
Dz dopamine agonist apomorphine could be completely 
blocked by the concurrent administration of the dopa-
mine D 1 receptor antagonist SCH 23390 (Mattingly et al. 
1991). This finding suggests that repeated stimulation of 
the Dz receptor alone is not sufficient to induce behavior-
al sensitization. In the present study, however, rats 
previously given daily quinpirole (3.0 mg/kg) treatments 
displayed a greater activity response to apomorphine 
than rats pretreated with only vehicle. Consistent with 
this result, it has recently been reported that rats are also 
more sensitive to the locomotor-activating effects of co-
caine after subchronic quinpirole pretreatments (Horger 
and Schenk 1991). These results, of course, clearly sug-
gest the involvement of Dz receptors in the development 
of behavioral sensitization. One possible explanation of 
these findings is that repeated quinpirole treatments in-
duce autoreceptor subsensitivity. Thus, when subse-
quently challenged with a mixed dopamine agonist such 
as apomorphine or cocaine, there is a greater net increase 
in postsynaptic dopamine receptor stimulation, which in 
turn, leads to greater locomotor activity. Interestingly, 
autoreceptor tolerance or subsensitivity was one of the 
earliest explanations for the development of behavioral 
sensitization (Muller and Seeman 1979; Robinson and 
Becker 1986), and a number of behavioral, electrophysio-
logical, and neurochemical effects of repeated agonist 
treatments are consistent with this view (Rebec and Lee 
1982; Henry and White 1991; Rowlett et al. 1991). But 
while an autoreceptor subsensitivity argument appears 
plausible, this explanation cannot account for the fact 
that the 0.3 mg/kg dose of quinpirole used in the present 
study did not increase subsequent sensitivity to apomor-
phine. Like the 3.0 mg/kg dose, this low dose of quin-
pirole resulted in a significant inhibition in activity that 
diminished across the 10 pretreatment days (see Fig. 3). 
This finding suggests that the 0.3 mg/kg dose of quin-
pirole also induced autoreceptor subsensitivity. Yet, this 
dose of quinpirole did not increase subsequent sensitivity 
to apomorphine. Thus, although autoreceptor subsen-
sitivity may be a contributing factor to the development 
of sensitization, this latter finding suggests that some 
minimal level of postsynaptic Dz receptor stimulation is 
also necessary to produce this effect. Consistent with this 
view, other evidence suggests that autoreceptor tolerance 
cannot account exclusively for the development of be-
havioral sensitization to mixed dopamine agonists (see 
Robinson and Becker 1986; Mattingly et al. 1991; Row-
lett et al. 1991). Dopamine Dz antagonists, for example, 
do not block the development of sensitization to either 
apomorphine or amphetamine (Stewart and Vezina 
1989; Vezina and Stewart 1989; Mattingly et al. 1991). 
Interestingly, in experiment 3, the effect of repeated 
Dz receptor stimulation with quinpirole on subsequent 
sensitivity to apomorphine was completely blocked by 
the D 1 receptor antagonist, SCH 23390. This finding is 
consistent with previous work indicating that the de-
velopment of behavioral sensitization to mixed Di/Dz 
dopamine agonists, such as apomorphine and am-
phetamine, may also be prevented by the blockade ofD1 
dopamine receptors (Stewart and Vezina 1989; Vezina 
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and Stewart 1989; Mattingly et al. 1991). Taken together, 
these results suggest that repeated dopamine Dz receptor 
stimulation is neither necessary nor S:Ufficient for the 
induction of behavioral sensitization. However, in the 
presence of D 1 receptor "tone", as in experiment 2, re-
peated Dz stimulation may contribute to the magnitude 
of the sensitization effect. Whereas, in the absence ofD1 
"tone", repeated D 2 receptor stim-qlation will not 
produce behavioral sensitization (expt 3; Stewart and 
Vezina 1989; Mattingly et al. 1991). These results are 
consistent with the idea of an "enabliµg" function for 
dopamine D1-type receptors (see Clark and White 1987, 
for review). 
Although the above interpretation accounts for the 
present results as well as our previous findings using 
selective antagonists with repeated apomorphine treat-
ments (Mattingly et al. 1991), at least one alternative 
explanation should be noted. It could be argued, for 
example, that the ability of SCH 23390 to block the 
effects of repeated quinpirole or apomorphine treatments 
on subsequent sensitivity to apomorphine is due to a 
general depression of locomotor activity rather than to 
a specific blockade of dopamine D1 re~eptors (cf Hira-
bayasi et al. 1991). Although this explanation cannot be 
exclusively ruled out on the basis of thb present results, 
there are several arguments against this ~iew. First, many 
treatments which significantly reduce lotomotor activity 
do not block the development of behavioral sensitiza-
tion. For example, the dopamine Dz anfugonist sulpiride 
depresses activity and blocks the acute locomotor ac-
tivating effects of apomorphine, but does not prevent the 
development of behavioral sensitization to apomorphine 
(Mattingly et al. 1991). Likewise, low doses of apomor-
phine inhibit locomotor activity but siill result in the 
development of behavioral sensitization '(Mattingly et al. 
1988). Further, rats repeatedly treated with apomorphine 
in their home cage without any opportunity to explore 
the test environment display sensitization when subse-
quently challenged with apomorphine in the testing en-
vironment (Mattingly and Gotsick 1990). Also it may be 
noted that SKF 38393 treatments decreased activity in a 
dose-dependent manner in experiment l, but resulted in 
a greater activity response to a subsequent challenge dose 
ofapomorphine. Finally, we have recently found that the 
same dose of SCH 23390 used in the present study does 
not block the development of behavioral sensitization to 
cocaine (Mattingly et al. 1992). Thus, 'treatments that 
depress locomotor activity in the test chambers do not 
always prevent the development of behavioral sensitiza-
tion. 
In conclusion, the present results indicate that re-· 
peated stimulation of either the D 1-type or D,-type 
dopamine receptor can lead to greater activity in re-
sponse to the mixed dopamine agonist, apomorphine. 
These findings are consistent with the view that repeated 
D1 receptor stimulation is both necessary and sufficient 
to induce behavioral sensitization tq apomorphine. 
Along with previous findings, the preserit results suggest 
that while Dz receptor stimulation may not be necessary 
for the development of behavioral sensitization to apo-
morphine, it does contribute to the magnitude of the 
/ 
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effect. These findings lend additional support to the view 
that multiple pre- and postsynaptic mechanisms may be 
involved ill the development of behavioral sensitization 
to dopamine agonists (cf Henry and White 1991). 
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